glp 1 moa Glucagon-like peptide-1 Mechanisms of Action and Therapeutic

In microglia, this shifts polarization from pro-inflammatory to anti-inflammatory states, reducing phagocytic hyperactivity and cytokine release

doi: 10.3389/fendo.2022.1043789 Received 14 September 2022 Accepted 21 November 2022 Published 07 December 2022 Volume 13 - 2022 Edited by Luigi Santacroce, University of Bari Aldo Moro, Italy Reviewed by Marialetizia Rastelli, Universit de Lille, France

and ameliorated glucose tolerance through increasing the insulin secretion multiple by 51.3% after 15 min of glucose stimulation ( p = 0.07) (14)

Dose escalation must follow FDA-approved schedules and be guided by your glycemic control, tolerability, and individual clinical factors to ensure safety and effectiveness

This once-weekly injectable medication is FDA-approved for weight management under the name Wegovy and for diabetes management under the name Ozempic

Who Should Not Take GLP-1 Agonist Drugs